Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Deloitte
Merck
US Army
Novartis
Accenture
Cipla
Chinese Patent Office
Cerilliant

Generated: February 17, 2018

DrugPatentWatch Database Preview

Aclaris Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ACLARIS THERAPS INC, and when can generic versions of ACLARIS THERAPS INC drugs launch?

ACLARIS THERAPS INC has one approved drug.

There are two US patents protecting ACLARIS THERAPS INC drugs.

There are twenty-four patent family members on ACLARIS THERAPS INC drugs in fourteen countries and six supplementary protection certificates in five countries.

Summary for Aclaris Theraps Inc
International Patents:24
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Aclaris Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aclaris Theraps Inc ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up
Aclaris Theraps Inc ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 RX Yes Yes 9,675,639 ➤ Sign Up Y ➤ Sign Up
Aclaris Theraps Inc ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 RX Yes Yes 7,381,427 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Aclaris Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,138,146 Acrochordon alleviation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Aclaris Theraps Inc Drugs

Supplementary Protection Certificates for Aclaris Theraps Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/008 United Kingdom ➤ Sign Up PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026
/1998 Austria ➤ Sign Up PRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
C/GB99/001 United Kingdom ➤ Sign Up PRODUCT NAME: CLOPIDOGREL HYDROGEN SULPHATE, THE DEXTROROTATORY ISOMER OF ALPHA-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRID-5-YL)(2-CHLOROPHENYL) METHYL ACETATE AS THE HYDROGEN SULPHATE SALT; REGISTERED: UK EU/1/98/069/001 19980715; UK EU/1/98/069/002 19980715; UK EU/1/98/069/003 19980715
C0036 Belgium ➤ Sign Up PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
C0036 France ➤ Sign Up PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
2012 00019 Denmark ➤ Sign Up PRODUCT NAME: RILPIVIRIN OG FARMACEUTISK ACCEPTABLE ADDITIONSSALTE DERAF, HERUNDER HYDROGENCHLORIDSALTET AF RILPIVIRIN; REG. NO/DATE: EU/1/11/736/001 20111128
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Federal Trade Commission
Covington
Mallinckrodt
Cerilliant
Citi
Medtronic
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot